Extracellular Matrix Proteomics Identifies Molecular Signature of Symptomatic Carotid Plaques

Sarah R. Langley,Karin Willeit,Athanasios Didangelos,Ljubica Perisic Matic,Philipp Skroblin,Javier Barallobre-Barreiro,Mariette Lengquist,Gregor Rungger,Alexander Kapustin,Ludmilla Kedenko,Chris Molenaar,Ruifang Lu,Temo Barwari,Gonca Suna,Xiaoke Yin,Bernhard Iglseder,Bernhard Paulweber,Peter Willeit,Joseph Shalhoub,Gerard Pasterkamp,Alun H. Davies,Claudia Monaco,Ulf Hedin,Catherine M. Shanahan,Johann Willeit,Stefan Kiechl,Manuel Mayr

DOI: https://doi.org/10.1172/jci86924

IF: 5.7

2017-01-01

Heart

Abstract:BACKGROUND. The identification of patients with high-risk atherosclerotic plaques prior to the manifestation of clinical events remains challenging. Recent findings question histology- and imaging-based definitions of the “vulnerable plaque,” necessitating an improved approach for predicting onset of symptoms. METHODS. We performed a proteomics comparison of the vascular extracellular matrix and associated molecules in human carotid endarterectomy specimens from 6 symptomatic versus 6 asymptomatic patients to identify a protein signature for high-risk atherosclerotic plaques. Proteomics data were integrated with gene expression profiling of 121 carotid endarterectomies and an analysis of protein secretion by lipid-loaded human vascular smooth muscle cells. Finally, epidemiological validation of candidate biomarkers was performed in two community-based studies. RESULTS. Proteomics and at least one of the other two approaches identified a molecular signature of plaques from symptomatic patients that comprised matrix metalloproteinase 9, chitinase 3-like-1, S100 calcium binding protein A8 (S100A8), S100A9, cathepsin B, fibronectin, and galectin-3-binding protein. Biomarker candidates measured in 685 subjects in the Bruneck study were associated with progression to advanced atherosclerosis and incidence of cardiovascular disease over a 10-year follow-up period. A 4-biomarker signature (matrix metalloproteinase 9, S100A8/S100A9, cathepsin D, and galectin-3-binding protein) improved risk prediction and was successfully replicated in an independent cohort, the SAPHIR study. CONCLUSION. The identified 4-biomarker signature may improve risk prediction and diagnostics for the management of cardiovascular disease. Further, our study highlights the strength of tissue-based proteomics for biomarker discovery. FUNDING. UK: British Heart Foundation (BHF); King’s BHF Center; and the National Institute for Health Research Biomedical Research Center based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London in partnership with King’s College Hospital. Austria: Federal Ministry for Transport, Innovation and Technology (BMVIT); Federal Ministry of Science, Research and Economy (BMWFW); Wirtschaftsagentur Wien; and Standortagentur Tirol.